Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
J Berdeja, F Palandri, MR Baer, D Quick, JJ Kiladjian… - Leukemia research, 2018 - Elsevier
Abstract Background The Philadelphia chromosome-negative myeloproliferative neoplasms
(MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting
from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-
molecule inhibitor of JAK2 that has potential dose-dependent selectivity for the JAK2 V617F
mutation and may inhibit additional JAK2 mutant isoforms in nonclinical testing. Methods A
multicenter, single-arm, outpatient phase 2 study evaluated the efficacy, safety, and …
(MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting
from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-
molecule inhibitor of JAK2 that has potential dose-dependent selectivity for the JAK2 V617F
mutation and may inhibit additional JAK2 mutant isoforms in nonclinical testing. Methods A
multicenter, single-arm, outpatient phase 2 study evaluated the efficacy, safety, and …
